Email Updates

You are here

2017: HIV Prevention Pipeline

Thursday, January 11, 2018
Antibody Related Research, HIV Vaccine, Microbicides, PrEP

While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.

This is an updated version of a graphic excerpted from Px Wire.